|Association between increment of serum VEGF level and prognosis after transcatheter arterial chemoembolization in hepatocellular carcinoma patients|
JH Shim, JW Park, JH Kim, M An, SY Kong, BH Nam, JI Choi, HB Kim, ...
Cancer science 99 (10), 2037-2044, 2008
|Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma|
YT Tai, BY Chang, SY Kong, M Fulciniti, G Yang, Y Calle, Y Hu, J Lin, ...
Blood, The Journal of the American Society of Hematology 120 (9), 1877-1887, 2012
|Lenalidomide targets clonogenic side population in multiple myeloma: pathophysiologic and clinical implications|
J Jakubikova, S Adamia, M Kost-Alimova, S Klippel, D Cervi, JF Daley, ...
Blood, The Journal of the American Society of Hematology 117 (17), 4409-4419, 2011
|Upregulated HSP27 in human breast cancer cells reduces Herceptin susceptibility by increasing Her2 protein stability|
SH Kang, KW Kang, KH Kim, B Kwon, SK Kim, HY Lee, SY Kong, ES Lee, ...
BMC cancer 8 (1), 286, 2008
|Blockade of the MEK/ERK signalling cascade by AS703026, a novel selective MEK1/2 inhibitor, induces pleiotropic anti‐myeloma activity in vitro and in vivo|
K Kim, SY Kong, M Fulciniti, X Li, W Song, S Nahar, P Burger, ...
British journal of haematology 149 (4), 537-549, 2010
|Targeting NAD+ salvage pathway induces autophagy in multiple myeloma cells via mTORC1 and extracellular signal-regulated kinase (ERK1/2) inhibition|
M Cea, A Cagnetta, M Fulciniti, YT Tai, T Hideshima, D Chauhan, ...
Blood, The Journal of the American Society of Hematology 120 (17), 3519-3529, 2012
|Association between vascular endothelial growth factor gene polymorphisms and survival in hepatocellular carcinoma patients|
SY Kong, JW Park, JA Lee, JE Park, KW Park, EK Hong, CM Kim
Hepatology 46 (2), 446-455, 2007
|Breast cancer diagnosis using a microfluidic multiplexed immunohistochemistry platform|
MS Kim, T Kim, SY Kong, S Kwon, CY Bae, J Choi, CH Kim, ES Lee, ...
PloS one 5 (5), e10441, 2010
|Dual inhibition of canonical and noncanonical NF-ęB pathways demonstrates significant antitumor activities in multiple myeloma|
C Fabre, N Mimura, K Bobb, SY Kong, G Gorgun, D Cirstea, Y Hu, ...
Clinical Cancer Research 18 (17), 4669-4681, 2012
|Predicting tissue HER2 status using serum HER2 levels in patients with metastatic breast cancer|
SY Kong, BH Nam, KS Lee, Y Kwon, ES Lee, MW Seong, DH Lee, J Ro
Clinical chemistry 52 (8), 1510-1515, 2006
|Prognostic implications of tumor-infiltrating lymphocytes in association with programmed death ligand 1 expression in early-stage breast cancer|
IH Park, SY Kong, JY Ro, Y Kwon, JH Kang, HJ Mo, SY Jung, S Lee, ...
Clinical breast cancer 16 (1), 51-58, 2016
|Elevated red blood cell distribution width as a simple prognostic factor in patients with symptomatic multiple myeloma|
H Lee, SY Kong, JY Sohn, H Shim, HS Youn, S Lee, HJ Kim, HS Eom
BioMed research international 2014, 2014
|Serum HE4 level is an independent prognostic factor in epithelial ovarian cancer|
SY Kong, MH Han, HJ Yoo, JH Hwang, MC Lim, SS Seo, CW Yoo, JH Kim, ...
Annals of surgical oncology 19 (5), 1707-1712, 2012
|CYP2A6 and ERCC1 polymorphisms correlate with efficacy of S-1 plus cisplatin in metastatic gastric cancer patients|
SR Park, SY Kong, BH Nam, IJ Choi, CG Kim, JY Lee, SJ Cho, YW Kim, ...
British journal of cancer 104 (7), 1126-1134, 2011
|Low initial human papilloma viral load implicates worse prognosis in patients with uterine cervical cancer treated with radiotherapy|
JY Kim, S Park, BH Nam, JW Roh, CH Lee, YH Kim, HJ Shin, SK Lee, ...
Journal of clinical oncology 27 (30), 5088-5093, 2009
|BRCA1 and BRCA2 germline mutations in Korean ovarian cancer patients|
MC Lim, S Kang, SS Seo, SY Kong, BY Lee, SK Lee, SY Park
Journal of cancer research and clinical oncology 135 (11), 1593-1599, 2009
|Serum HER-2 concentration in patients with primary breast cancer|
SY Kong, JH Kang, Y Kwon, HS Kang, KW Chung, SH Kang, DH Lee, ...
Journal of clinical pathology 59 (4), 373-736, 2006
|Glutathione-S-transferase genotypes influence the risk of chemotherapy-related toxicities and prognosis in Korean patients with diffuse large B-cell lymphoma|
HJ Cho, HS Eom, HJ Kim, IS Kim, GW Lee, SY Kong
Cancer genetics and cytogenetics 198 (1), 40-46, 2010
|Potent in vitro and in vivo activity of an Fc-engineered humanized anti-HM1. 24 antibody against multiple myeloma via augmented effector function|
YT Tai, HM Horton, SY Kong, E Pong, H Chen, S Cemerski, MJ Bernett, ...
Blood, The Journal of the American Society of Hematology 119 (9), 2074-2082, 2012
|Identification of hypoxanthine as a urine marker for non-Hodgkin lymphoma by low-mass-ion profiling|
BC Yoo, SY Kong, SG Jang, KH Kim, SA Ahn, WS Park, S Park, T Yun, ...
BMC cancer 10 (1), 55, 2010